Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 20 ... to our national sponsors for their support of these family health events. We thank AstraZeneca for helping us make heart health information available, Univision Communications for ...
2009 NOV 23 ... ... Living With Bipolar Depression campaign. The nationwide program is sponsored by AstraZeneca (NYSE:AZN) as part of its ongoing efforts to raise awareness of mental illness. ...
2009 NOV 23 ... The lawsuits also name several leading pharmaceutical companies, including London-based AstraZeneca (NYSE:AZN), Abbott Park, Ill.-based Abbott Laboratories (NYSE:ABT), Schaumburg, ...
2009 NOV 23 ... Jan M. Lundberg, Ph.D., executive vice president and head of global discovery research, AstraZeneca, is to become his successor. Paul is committed to working closely with Lundberg to ...
2009 NOV 23 ... from Netherlands, "In budesonide/formoterol (Symbicort ® Turbuhaler ®, AstraZeneca, Lund, Sweden) maintenance and reliever therapy ( SMART), patients with asthma take a ...
2009 NOV 27 ... in good yields (> 70%) and high strength (> 98% w/w)," wrote P.J. Hogan and colleagues, AstraZeneca.The researchers concluded: "The aqueous process, which is additionally ...
2009 NOV 16 ... such as Cephalon's CEP-701, are in phase 1 and 2 clinical trials, and a series of AstraZeneca Trk inhibitors are poised to enter the clinic. As monotherapy, inhibitors may be ...
2009 NOV 16 ... E. Competition in the Industry F. Leading Players in the Market F.1 AstraZeneca Plc F.2 Pfizer Inc F.3 Novartis AG G. Appendix G.1 Offshoring in the ...
2009 NOV 16 ... E. Competition in the Industry F. Leading Players in the Market F.1 AstraZeneca Plc F.2 GlaxoSmithKline Plc F.3 Pfizer Inc G. Appendix G.1 Offshoring in ...
2009 NOV 16 ... multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available ...
2009 NOV 16 ... that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca's clinical pharmacology studies ...
2009 NOV 23 ... brings extensive experience in sales and marketing from his sixteen year tenure at AstraZeneca Pharmaceuticals. From 2003 to 2006, Beamish served as executive director, commercial ...
2009 NOV 23 ... cancer. "PARP inhibitors, which include Sanofi-Aventis's BSI-201 and AstraZeneca's olaparib, could dramatically improve prognoses for the woefully underserved patient ...
2009 NOV 23 ... well as transfer of certain technologies from Tianda. Rosuvastatin was first marketed by Astrazeneca as Crestor in 2003 and is an effective statin to treat high cholesterol and related ...
2009 NOV 16 ... esomeprazole and ASA in combination was well tolerated," wrote M. Niazi and colleagues, AstraZeneca. The researchers concluded: "There was no pharmacokinetic interaction ...
2009 NOV 23 ... anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM® I.V. (meropenem for injection) in ...
2009 NOV 16 ... Prior to joining NEA, he was President and CEO of MedImmune, which was acquired by AstraZeneca for $15.6 billion in 2007. During his 16 years at MedImmune, it grew from a small ...
